CHILDRENS CANCER GROUP

儿童癌症组

• 批准号: 2009150
• 负责人: Leonard Stanley Sender
• 金额: $ 5.45万
• 依托单位: CHILDREN'S HOSPITAL OF ORANGE COUNTY
• 依托单位国家: 美国
• 财政年份: 1996
• 资助国家: 美国
• 起止时间: 1996-04-25 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2009150
• 关键词: 6 thiopurine; Burkitt's lymphoma; Ewing's tumor; Hodgkin's disease; Wilms' tumor; XomaZyme; acivicin; acute leukemia; acute lymphocytic leukemia; acute myelogenous leukemia; adolescence (12-20); antineoplastics; asparaginase; astrocytoma; biological response modifiers; bone marrow transplantation; brain neoplasms; cancer registry /resource; cancer risk; central nervous system neoplasms; child (0-11); chronic myelogenous leukemia; cis platinum compound; clinical research; clinical trial phase I; colony stimulating factor; combination cancer therapy; combination chemotherapy; cooperative study; cyclophosphamide; cyclosporines; cytokine; cytosine arabinoside; daunorubicin; deferoxamine; deoxycoformycin; doxorubicin; drug screening /evaluation; enalapril; ependymoma; etoposide; fazarabine; fluorouracil; germ cell neoplasms; glioma; hematopoiesis; hematopoietic stem cells; hepatoblastoma; hepatocellular carcinoma; human genetic material tag; human immunodeficiency virus 1; human subject; human therapy evaluation; human tissue; ifosfamide; interferons; interleukin 12; interleukin 15; interleukin 2; medulloblastoma; melphalan; metastasis; methotrexate; mitoxantrone; molecular oncology; neoplasm /cancer chemotherapy; neoplasm /cancer classification /staging; neoplasm /cancer epidemiology; neoplasm /cancer genetics; neoplasm /cancer immunology; neoplasm /cancer immunotherapy; neoplasm /cancer pharmacology; neoplasm /cancer radiation therapy; neoplasm /cancer relapse /recurrence; neoplasm /cancer surgery; neuroblastoma; nonHodgkin's lymphoma; osteosarcoma; paclitaxel; pediatric pharmacology; podophyllin; prednisone; retinoate; rhabdomyosarcoma; tissue resource /registry; topotecan; trimetrexate; vincristine

Children's Hospital of Orange County (CHOC) was only recently approved as a full member institution (April 1993) in Childrens Cancer Group (CCG). Despite being a full member for only eighteen months, CHOC investigators have contributed significantly to the development of new therapeutic protocols, the establishment of two reference laboratories, and have provided significant scientific and administrative leadership within CCG. CHOC currently registers all eligible patients on to CCG protocols and is an approved CCG phase I and Bone Marrow Transplant institution. The long- term objective of this proposal is to further the improvement in the prevention, diagnosis, and treatment of childhood cancer through participation in CCG. The specific aims of this proposal include: l) providing leadership in several strategy groups, discipline committees, and study committees; 2) expanding the reference laboratories for lymphoma studies and hematopoiesis/cytokine translational research; 3) providing leadership and implementation of group phase I trials; and 4) developing pilot studies that can be translated and implemented into groupwide studies. There are presently 7 investigators at CHOC participating in 32 committee appointments. The recruitment of additional CHOC investigators will provide additional scientific and administrative CCG leadership at the level of the strategy group, study chair, study vice chair, and within scientific and discipline committees. The CHOC Hematopoisis/Cytokine Laboratory will continue to investigate stem cell regulation and cytokine receptor modulation, develop methods for ex vivo isolation and expansion of stem cells (CD34), and optimize the mobilization of peripheral stem cells for repetitive submyeloablative therapy. The Lymphoma Reference Laboratory will continue to investigate the oncogenesis of childhood lymphomas and develop alternative treatment strategies, including antisense gene therapy for Burkitt's lymphoma. Pilot phase I trials in biotherapy, immunotherapy, and hematopoiesis, including lL-2 and activated leukocytes, IL-12 + IL-15 immunotherapy, auto-graft-vs-host tumor induction, and the use of new cytokines, including thrombopoietin, will be explored at CHOC and will potentially lead to groupwide studies. In summary, CHOC will continue to provide leadership for pilot studies through CCG, participate in all open CCG phase I, II, III, and bone marrow transplant studies, develop protocols for determining the long-term effects of chemo-radiotherapy and immunotherapy, and conduct specific biological investigations in the areas of experimental hematopoiesis and childhood lymphoma.

奥兰治县儿童医院 (CHOC) 最近才被批准为 儿童癌症组 (CCG) 的正式成员机构（1993 年 4 月）。 尽管成为正式会员仅十八个月，CHOC 调查员 对新疗法的开发做出了重大贡献 协议，建立两个参考实验室，并拥有 在 CCG 内提供了重要的科学和行政领导。 CHOC 目前将所有符合资格的患者注册到 CCG 协议上，并且正在 经批准的 CCG 一期和骨髓移植机构。长- 该提案的长期目标是进一步改进 儿童癌症的预防、诊断和治疗 参与CCG。该提案的具体目标包括： l) 在多个战略小组、纪律委员会中提供领导， 和研究委员会； 2）扩大参考实验室 淋巴瘤研究和造血/细胞因子转化研究； 3） 领导和实施第一阶段试验；和 4) 开展可转化并实施的试点研究 全集团研究。 CHOC目前有7名调查员 参与 32 项委员会任命。额外招募 CHOC 调查人员将提供额外的科学和行政支持 CCG 战略组层面的领导、研究主席、研究 副主席以及科学和纪律委员会。 乔克 造血/细胞因子实验室将继续研究干细胞 调节和细胞因子受体调节，开发离体方法 干细胞（CD34）的分离和扩增，并优化 动员外周干细胞进行重复清髓性治疗 治疗。淋巴瘤参考实验室将继续调查 儿童淋巴瘤的肿瘤发生并开发替代治疗 策略，包括伯基特淋巴瘤的反义基因治疗。 生物疗法、免疫疗法和造血方面的试点一期试验， 包括IL-2和活化白细胞、IL-12 + IL-15免疫治疗、 自体移植物抗宿主肿瘤诱导，以及新细胞因子的使用， 包括血小板生成素，将在 CHOC 进行探索，并有可能 导致全组研究。综上所述，CHOC将继续提供 通过 CCG 领导试点研究，参与所有开放的 CCG I、II、III 期和骨髓移植研究，制定方案 用于确定放化疗的长期效果和 免疫疗法，并进行特定的生物学研究 实验性造血和儿童淋巴瘤领域。